BGI Genomics Co., Ltd. (300676.SZ) Bundle
From its founding in 1999 to its current status as 300676.SZ, BGI Genomics has scaled into one of the world's largest genomics organizations, operating in over 100 countries and serving more than 2,300 medical institutions, and its mission to strengthen prevention of genetic diseases, accelerate scientific innovation, and provide affordable genomics-powered health solutions drives every sequencing run and proteomics assay across research, clinical, drug-discovery and agricultural applications; headquartered in Shenzhen with major labs in Beijing, Tianjin, Wuhan, Shanghai and Guangzhou, BGI leverages thousands of partnerships across medical health, resource conservation and judicial services to pursue a vision of becoming a world leader in the age of life sciences and to translate genomics into real-world trans-omics impact for a better life while living by core values of Curiosity, Application of Knowledge and Working for the Betterment of Mankind
BGI Genomics Co., Ltd. (300676.SZ) - Intro
BGI Genomics Co., Ltd. (300676.SZ) is a leading global provider of genomic sequencing and proteomic services, established in 1999 and headquartered in Shenzhen, China. The company operates in over 100 countries and serves more than 2,300 medical institutions, offering a broad portfolio of genetic testing products and integrated sequencing services spanning basic research, clinical research, genetic testing, drug discovery, agriculture and other applied fields. BGI Genomics maintains branches and medical laboratories in major Chinese cities, including Beijing, Tianjin, Wuhan, Shanghai and Guangzhou, and has formed partnerships with thousands of organizations across medical health, resource conservation and judicial services. The company pursues trans-omics integration to translate genomic and proteomic achievements into real-world health and life improvements.- Founded: 1999
- Headquarters: Shenzhen, China
- Global footprint: Operations in 100+ countries
- Clinical customers: >2,300 medical institutions
- Application areas: Research, clinical, diagnostics, drug discovery, agriculture, forensics
| Dimension | Key Facts / Targets |
|---|---|
| Core business | Genomic sequencing, proteomics, genetic diagnostics, translational research services |
| Geographic presence | Headquarters in Shenzhen; major labs/branches in Beijing, Tianjin, Wuhan, Shanghai, Guangzhou; global clients in 100+ countries |
| Customer base | Over 2,300 medical institutions; thousands of collaborative organizations across disciplines |
| Strategic focus | Trans-omics integration, clinical translation, scalable diagnostics, precision medicine support |
| R&D & partnerships | Multi-disciplinary partnerships in medical health, conservation, judicial services; ongoing platform development for sequencing and proteomics |
Mission
- Translate genomic and proteomic insights into practical solutions for human health, agriculture and biodiversity.
- Provide accessible, accurate and scalable molecular diagnostics to support clinical decision-making worldwide.
- Advance trans-omics approaches to enable prevention, early detection and personalized treatment.
Vision
- To be the world's trusted engine for genomic and proteomic knowledge that empowers better health and sustainable life.
- To integrate multi-omics data streams into routine clinical and agricultural practice, reducing time from discovery to impact.
Core Values
- Scientific excellence - rigorous methods, reproducibility and continuous innovation in sequencing and proteomics.
- Accessibility - broad deployment of diagnostic and research tools to institutions globally, enabling equitable access.
- Collaboration - open partnerships with hospitals, research institutes, industry and public-sector stakeholders.
- Integrity - data security, ethical sample handling and compliance with clinical standards and regulations.
- Translation - focus on delivering actionable results that improve diagnosis, treatment and resource conservation.
| Value | Operational Expression | Example Metrics |
|---|---|---|
| Scientific excellence | Invest in platform development, SOPs and quality management | Sequencing throughput (global service capacity), assay validation rates |
| Accessibility | Deploy products to hospitals and labs; scale service networks | Presence in 100+ countries; >2,300 medical institution clients |
| Collaboration | Consortia, academic-industrial partnerships, cross-disciplinary projects | Thousands of partner organizations across health, conservation, judicial sectors |
| Integrity | Compliance programs, secure data governance, accredited labs | Clinical lab accreditations, audit pass rates |
| Translation | Commercial diagnostic kits, clinical pipelines, agricultural assays | Number of validated diagnostic products; clinical adoption rates |
BGI Genomics Co., Ltd. (300676.SZ) - Overview
BGI Genomics Co., Ltd. (300676.SZ) centers its corporate purpose on strengthening prevention and control of genetic diseases, accelerating scientific innovation, and equipping health professionals with advanced, affordable genomics diagnostics to improve human health and make genomics-powered solutions accessible to all. The company emphasizes translating genetic and technological achievements into real-world clinical and research applications, pursuing a trans-omics approach to a better life.- Mission: Strengthen prevention and control of genetic diseases; enable and accelerate scientific innovation; empower clinicians and researchers with advanced diagnostic tools.
- Vision: Democratize high-quality, affordable genomics technologies to advance life-science research and improve population health worldwide.
- Strategic focus: Clinical genomics, population screening, companion diagnostics, research-consumables, and bioinformatics/AI-driven interpretation.
- Accessibility: Deliver cost-effective genomics tests and screening programs to broaden public and clinical access.
- Translation: Move discoveries from lab to clinic via validated diagnostic products and service platforms.
- Integration: Pursue trans-omics integration (genomics, transcriptomics, proteomics, epigenomics) to enable precision prevention and personalized care.
- Quality & compliance: Maintain regulatory approvals and quality systems for clinical-grade sequencing and diagnostics.
| Metric | Latest reported / Approximate |
|---|---|
| Primary listing | Shenzhen Stock Exchange (300676.SZ) |
| Business segments | Clinical diagnostics, population screening, sequencing services, reagents & instruments, bioinformatics |
| Annual revenues (recent FYs) | Approximately RMB 3-4 billion (company reports 2021-2023 showing revenue growth in the low billions RMB range) |
| R&D intensity | High - sustained multi-year investment in assay development, platform optimization, and bioinformatics (R&D % of revenue typically in double digits) |
| Sample throughput | Millions of samples cumulatively processed across clinical and research projects (large-scale population screening and prenatal/oncology pipelines) |
- Scale preventive screening programs to reduce genetic-disease burden through early detection and carrier screening.
- Advance clinically actionable assays (prenatal, oncology, rare disease) with validated sensitivity/specificity and payor/clinical adoption strategies.
- Develop integrated data platforms combining multi-omics and AI to provide actionable reports for clinicians and researchers.
BGI Genomics Co., Ltd. (300676.SZ) - Mission Statement
BGI Genomics' mission is to translate genomic science into concrete health benefits for people worldwide by delivering high-quality, affordable genomics-powered solutions that accelerate research, strengthen disease prevention, and empower clinicians.- Apply cutting‑edge genomics and trans‑omics technologies to real-world medicine and public health.
- Expand access to population-scale screening, early diagnosis, and precision prevention.
- Drive scientific innovation through sustained investment in R&D and global collaboration.
- Deliver scalable, cost-effective diagnostic tools to strengthen prevention and control of genetic disease.
- Make genomics-driven health solutions widely accessible and affordable for diverse healthcare systems.
- Accelerate scientific discovery by integrating genomics, transcriptomics, proteomics and bioinformatics into clinical workflows.
- Empower health professionals with advanced diagnostics and decision-support tools to improve patient outcomes.
| Strategic Pillar | Objective | Representative KPI / Recent Data |
|---|---|---|
| Clinical Genomics | Scale diagnostic services for prenatal, oncology, and rare disorders | Over 8 million NIPT and clinical tests performed cumulatively (company disclosures); prenatal testing market share leadership in China |
| R&D & Innovation | Advance trans‑omics platforms and bioinformatic pipelines | R&D spend ~15-18% of revenue in recent fiscal years; several hundred patents and patent applications globally |
| Public Health & Population Screening | Support large cohort studies and national screening programs | Participation in multi‑million sample projects and pathogen surveillance initiatives (COVID‑19 sequencing >100,000 genomes during peak response periods) |
| Commercial & Global Expansion | Broaden market access and partnerships | Listed on Shenzhen Stock Exchange (300676.SZ); market cap in the low tens of billions RMB range depending on market; diversified revenue from services, reagents, and instruments |
- Public listing: Shenzhen Stock Exchange, ticker 300676.SZ.
- Revenue drivers: clinical testing services, reagent & instrument sales, genome sequencing services, and bioinformatic solutions.
- R&D emphasis: consistent multi‑year investment to support platform enhancements and new assay development.
- Global footprint: operations and collaborations spanning Asia, Europe, Africa, and the Americas, with strategic partners in academic and clinical networks.
- Prevention: expanded prenatal and newborn screening programs to reduce incidence and impact of genetic disease.
- Diagnosis: shorter turnaround times and improved diagnostic yield for rare and oncologic disorders through integrated genomics.
- Research acceleration: large genomic datasets and analytic platforms that enable trans‑omics discoveries and drug target identification.
- Health equity: commercialization strategies aimed at lowering per‑test cost and increasing accessibility in under‑served regions.
BGI Genomics Co., Ltd. (300676.SZ) - Vision Statement
BGI Genomics Co., Ltd. (300676.SZ) commits to a future where trans-omics insights transform prevention, diagnosis and treatment across populations. The company's vision centers on translating genomic knowledge into affordable, scalable health solutions that strengthen genetic disease prevention, accelerate scientific innovation, and empower clinicians and public-health systems worldwide. Core Values- Curiosity - relentless pursuit of new biological and technological frontiers through hypothesis-driven research and open inquiry.
- Application of Knowledge - translating discoveries into validated clinical and public-health products, workflows and services.
- Working for the Betterment of Mankind - prioritizing equitable access to genomics-powered health tools that lower barriers to precision medicine.
- Advance prevention and control of genetic diseases by expanding screening reach - target: scale newborn and carrier screening programs to cover millions annually.
- Enable and accelerate scientific innovation via partnerships and platform capabilities - target: grow collaborative projects with academic and clinical partners by ≥20% year-on-year.
- Empower health professionals with diagnostics - target: increase clinical-grade test throughput and shorten report turnaround time by ≥30% across core offerings.
- Make genomics-powered health solutions affordable - target: sustain or reduce average per-test pricing while improving sensitivity/specificity metrics.
| Metric | Target / Example |
|---|---|
| R&D investment intensity (R&D/Revenue) | ~18-22% of revenue focused on NGS, microarray and multi‑omics platform development |
| Annual test throughput | Millions of samples processed globally across newborn screening, reproductive health and oncology panels |
| Clinical turnaround time | Target reductions of ~30% for core diagnostic panels via automation and bioinformatics optimization |
| Access & affordability | Progressively lower per-test cost through scale economies and reagent/platform improvements |
| Global collaborations | Dozens of institutional partnerships across research hospitals, universities and public-health agencies |
- Curiosity fuels platform breadth - investment in sequencing, single‑cell, proteomics and integrative bioinformatics to realize trans‑omics.
- Application of Knowledge ensures rigorous clinical validation, regulatory compliance, and deployment pathways from lab to point-of-care.
- Working for the Betterment of Mankind shapes pricing, public‑health screening programs, and training initiatives that broaden clinical uptake.
| Area | Illustrative Indicator | Ambition |
|---|---|---|
| Genetic disease prevention | Number of newborns/carriers screened annually | Scale to millions per year |
| Research enablement | Publications & collaborative projects leveraging company platforms | Yearly growth in high‑impact papers and consortia memberships |
| Clinical diagnostics | Tests delivered across oncology, reproductive health, rare disease | Increase market share via validated panels and faster TAT |
- Reinvest a significant proportion of revenue into R&D to sustain platform competitiveness and lower unit costs.
- Scale manufacturing and automation to achieve cost leadership in high-volume assays.
- Expand training and support for clinicians and public-health partners to ensure correct test utilization and result interpretation.
BGI Genomics Co., Ltd. (300676.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.